Guided Therapeutics, Inc. (OTC: QB GTHP) is committed to developing groundbreaking medical devices using our patented biophotonic technology to detect diseases earlier, more accurately, and more efficiently than other tests.
Our products are designed to improve the patient’s experience, provide the physician with more powerful tools, improve the efficiency of the healthcare system and increase shareholder value.
How we are making
a difference globally
Our products are designed to:
Improve the patient’s experience.
Provide the physician with more powerful tools.
Improve the efficiency of the healthcare system.
Our patented technology, which features our flagship product the LuViva® Advanced Cervical Scan, uses biophotonics to detect both physical and chemical changes in tissues that are early signs of cancer.
Cancer screening is a compelling market opportunity proven to save lives. As a pioneering company in this space, GTI represents an excellent investment.
Join our network of Investors
We are actively seeking new investors to join our network. We provide full transparency into our organization and would love to have you join.
We’re international and expanding. Read about Guided Therapeutics
Recent Press Releases
GTI Provides Update on Start of Clinical Trial for US FDA Approval
May 01, 2023
GTI Signs Agreement to Begin Clinical Trial for US FDA Approval
Dec 23, 2022
Guided Therapeutics Closes $3.3 Million Bridge Financing
Sep 07, 2022
Guided Therapeutics Receives Institutional Review Board Approval to Start Clinical Study for FDA Approval of the LuViva® Advanced Cervical Scan
Jul 20, 2022